Axiomer® platform applicability and potential in therapeutically relevant models for targeted RNA editing presented at TIDES EU 2018 by Antti Aalto - ProQR Therapeutics
… of the communities we serve. Our proprietary Axiomer™ RNA editing technology platform enables the editing of … in RNA using the cells own editing machinery. Axiomer RNA editing technology harnesses ADAR (Adenosine Deaminase … currently untreatable diseases. By harnessing the power of RNA editing, we aim to create a world where genetics inform …
… of the communities we serve. Our proprietary Axiomer™ RNA editing technology platform enables the editing of … in RNA using the cells own editing machinery. Axiomer RNA editing technology harnesses ADAR (Adenosine Deaminase … currently untreatable diseases. By harnessing the power of RNA editing, we aim to create a world where genetics inform …
… of the communities we serve. Our proprietary Axiomer™ RNA editing technology platform enables the editing of … in RNA using the cells own editing machinery. Axiomer RNA editing technology harnesses ADAR (Adenosine Deaminase … currently untreatable diseases. By harnessing the power of RNA editing, we aim to create a world where genetics inform …
… of the communities we serve. Our proprietary Axiomer™ RNA editing technology platform enables the editing of … in RNA using the cells own editing machinery. Axiomer RNA editing technology harnesses ADAR (Adenosine Deaminase … currently untreatable diseases. By harnessing the power of RNA editing, we aim to create a world where genetics inform …
Chardan’s 9th Annual Genetic Medicines Conference – October 21, 2025
Company management will participate in an RNA Editing panel at 1:00 p.m. ET and will conduct 1x1 investor meetings in conjunction with the conference.
ProQR will host a virtual Analyst and Investor Event on Wednesday, December 11, 2024 from 10:00 am until approximately 12:30 pm EST, including an Analyst Q&A session with members of the ProQR Management Team.
ProQR has announced the completion of an in-depth strategic review designed to deliver on our commitment to advance RNA therapies for diseases with high unmet need. We are also sharing additional analyses of the sepofarsen Illuminate trial.
